Sign in or create an account to add this stock to your watchlist.
About Mirati Therapeutics (OTCMKTS:MYLGF)
MethylGene, Inc. operates as a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for cancer and infectious disease.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Mirati Therapeutics (OTCMKTS:MYLGF) Frequently Asked Questions
What is Mirati Therapeutics' stock symbol?
Mirati Therapeutics trades on the OTCMKTS under the ticker symbol "MYLGF."
Who are Mirati Therapeutics' key executives?
Mirati Therapeutics' management team includes the folowing people:
- Martin Godbout Ph.D, Chairman of the Board (Age 57)
- Charles M. Baum M.D., Ph.D., President, Chief Executive Officer, Director (Age 55)
- Mark J. Gergen, Chief Operations Officer, Executive Vice President (Age 51)
- Rachel W. Humphrey M.D., Chief Medical Officer, Executive Vice President (Age 51)
- Jamie A. Donadio, Vice President - Finance (Age 38)
- Henry J. Fuchs M.D., Ph.D., Independent Director (Age 55)
- Rodney W. Lappe Ph.D., Independent Director (Age 58)
- Peter A. Thompson M.D., Independent Director (Age 53)
Has Mirati Therapeutics been receiving favorable news coverage?
News articles about MYLGF stock have trended positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mirati Therapeutics earned a news sentiment score of 0.42 on Accern's scale. They also gave media coverage about the company an impact score of 46.47 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Mirati Therapeutics?
Shares of MYLGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mirati Therapeutics' stock price today?
One share of MYLGF stock can currently be purchased for approximately $6.07.
How big of a company is Mirati Therapeutics?
Mirati Therapeutics has a market capitalization of $70.20 million.
MarketBeat Community Rating for Mirati Therapeutics (MYLGF)MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MYLGF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYLGF will underperform the S&P 500 over the long term. You may vote once every thirty days.
Mirati Therapeutics (OTCMKTS:MYLGF) Analyst Ratings History
(Data available from 5/27/2016 forward)
Mirati Therapeutics (OTCMKTS:MYLGF) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Mirati Therapeutics (OTCMKTS MYLGF) Insider Trading and Institutional Ownership History
Mirati Therapeutics (OTCMKTS MYLGF) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Mirati Therapeutics (OTCMKTS MYLGF) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Mirati Therapeutics (OTCMKTS:MYLGF) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Mirati Therapeutics (OTCMKTS MYLGF) Stock Chart for Sunday, May, 27, 2018